Long-term clinical benefit of mavacamten for hypertrophic cardiomyopathy in a patient with RAF1-associated Noonan syndrome—case report Authors: Hanna M Seghers, Bert Ectors, Maaike Alaerts, Johan Saenen, Emeline M Van Craenenbroeck Published: 2026 ABSTRACT AbstractBackgroundHypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy and is frequently complicated by left ventricular outflow tract (LVOT) obstruction. While most cases are caused by sarcomeric mutations, up to 10% represent non-sarcomeric or syndromic phenocopies, including Noonan syndrome (NS). Noonan syndrome is a RASopathy in which mutations in genes such as RAF1 predispose to HCM through dysregulation of the Ras/MAPK pathway and are often associated with severe LVOT obstruction. Cardiac myosin inhibitors have demonstrated efficacy in sarcomeric obstructive HCM, but patients with syndromic HCM were excluded from pivotal clinical trials.Case summaryWe report a 29-year-old woman with long-standing obstructive HCM and NYHA class III symptoms, angina, and dizziness. Multimodality imaging demonstrated asymmetric septal hypertrophy (maximal wall thickness 20 mm), focal intramural late gadolinium enhancement, and dynamic LVOT obstruction reaching 55 mmHg during exercise. Owing to progressive obstruction, the patient was enrolled in the EXPLORER-HCM trial. During follow-up exceeding 5 years, treatment resulted in sustained reduction of LVOT gradients, improvement in functional status to NYHA class II, and complete resolution of angina and presyncope, without adverse effects. Genetic testing performed during trial participation identified a heterozygous likely pathogenic RAF1 variant, confirming Noonan syndrome-associated HCM.DiscussionThis case report demonstrates durable clinical and haemodynamic benefit of myosin inhibition in RAF1-associated Noonan syndrome HCM. This finding suggests that possible downstream hypercontractility may represent a shared and therapeutically targetable mechanism across sarcomeric HCM and selected syndromic phenocopies. Syndromic HCM associated with Noonan syndrome may present with obstructive physiology indistinguishable from sarcomeric HCM. Syndromic HCM associated with Noonan syndrome may present with obstructive physiology indistinguishable from sarcomeric HCM. Myosin inhibition with mavacamten resulted in sustained improvement in symptoms and LVOT obstruction in a patient with RAF1-associated Noonan syndrome HCM. Myosin inhibition with mavacamten resulted in sustained improvement in symptoms and LVOT obstruction in a patient with RAF1-associated Noonan syndrome HCM. These observations are hypothesis-generating, and further research into myosin inhibition across non-sarcomeric HCM phenocopies is warranted. These observations are hypothesis-generating, and further research into myosin inhibition across non-sarcomeric HCM phenocopies is warranted. Introduction Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy, characterized by otherwise unexplained left ventricular (LV) hypertrophy and a highly variable clinical presentation, ranging from asymptomatic disease to heart failure, arrhythmias, and sudden cardiac death.1–3 Approximately two-thirds of patients develop left ventricular outflow tract (LVOT) obstruction at rest or with provocation, encompassing obstructive HCM (oHCM). Most adult cases of HCM are caused by pathogenic variants in sarcomeric genes; however, up to 10% represent non-sarcomeric or syndromic phenocopies.4 Among these, Noonan syndrome (NS) is a RASopathy caused by germline variants affecting the Ras/MAPK signalling pathway and is frequently complicated by HCM. Mutations in RAF1, present in a minority of NS patients, are strongly associated with HCM and often confer an obstructive phenotype.5 Cardiac myosin inhibitors (CMIs) have recently transformed the treatment of symptomatic oHCM by directly targeting sarcomere hypercontractility underlying classical sarcomeric HCM, stabilizing the super-relaxed (SRX) state of myosin heads, and reducing the energy-consuming heads in the disordered-relaxed (DRX) state. Mavacamten has demonstrated reductions in LVOT gradients and improvements in functional capacity in sarcomeric HCM. However, patients with HCM phenocopies and syndromic HCM, including NS-associated cardiomyopathy, were excluded from pivotal trials, leaving uncertainty about CMI applicability in these populations.6,7 Here, we report a case of long-standing oHCM in a patient with NS who experienced sustained clinical and haemodynamic benefit from mavacamten therapy over more than 5 years of follow-up. Summary figure Case presentation History at presentation A 29-year-old woman was referred to our cardiomyopathy clinic in 2015 after relocating from the United States, where she had been followed for HCM, diagnosed at 6 months of age. At presentation, she reported fatigue, NYHA class III dyspnoea, intermittent angina, and dizziness. Her medical history included syncope at 14 years of age, migraine, depression, and obesity (height 165 cm, weight 130 kg, BMI 48). There was no family history of sudden cardiac death before the age of 45 years. She was being treated with propranolol 20 mg/day and verapamil 240 mg/day. Genetic testing had not previously been performed, as she had declined venepuncture because of trypanophobia. Investigations Electrocardiography did not show classical features of HCM. Cardiac magnetic resonance imaging (CMR) demonstrated asymmetric septal hypertrophy with a maximal wall thickness of 20 mm, and limited, localized intramural late gadolinium enhancement (LGE) (Figure 1). Supine bicycle echocardiography revealed chordal systolic anterior motion of the mitral valve with a dynamic intracavitary gradient of 2 mmHg at rest, 9 mmHg during Valsalva manoeuvre, and 55 mmHg during early recovery, confirming obstructive physiology. Four-day ambulatory rhythm monitoring did not reveal ventricular arrhythmias. Based on these findings, her estimated 5-year sudden cardiac death risk was calculated at 7.2% according to the HCM Risk-SCD prediction model. Implantation of an ICD was recommended; however, the patient deferred the procedure for personal reasons. Cardiac magnetic resonance imaging demonstrating asymmetric septal hypertrophy with a maximal wall thickness of 20 mm (A, short-axis cine) and focal intramural late gadolinium enhancement within the hypertrophied septum (B), consistent with hypertrophic cardiomyopathy and without features suggestive of infiltrative disease. Follow-up and treatment Over the subsequent 3 years, the patient remained clinically stable, with modest improvement in dyspnoea to the NYHA class II after cessation of propranolol, and under verapamil 240 mg daily and disopyramide 200 mg twice daily. With progression of LVOT obstruction (peak LVOT gradient of 73 mmHg during early recovery after exercise, Figure 2), she was enrolled in the EXPLORER-HCM trial. Disopyramide was discontinued per protocol. Although genetic testing had previously been deferred due to longstanding trypanophobia, the patient decided to gradually confront her fear of venepuncture in the context of trial participation. Echocardiography. Parasternal long-axis view demonstrating left ventricular hypertrophy (A). Supine bicycle stress echocardiography before inclusion in the EXPLORER-HCM trial (2019), demonstrating dynamic left ventricular outflow tract obstruction with a peak gradient of 73 mmHg (B). After completion of the double-blind phase and a temporary interruption related to the COVID-19 pandemic, she transitioned into the open-label long-term extension study in June 2020. At baseline of the open-label phase, she again reported NYHA class III symptoms, with echocardiographic LVOT gradients of 15 mmHg at rest and 49 mmHg during Valsalva. Within 4 weeks of initiating mavacamten, LVOT gradients decreased to 10 mmHg at rest and 28 mmHg with Valsalva. Functional status improved to NYHA class II within 3 months, and chest pain and dizziness resolved completely. A timeline of key clinical events and cardiac parameters after mavacamten initiation can be found in Table 1. Biochemical evaluation, performed during trial participation, did not reveal any secondary causes or metabolic conditions contributing to the patient’s obesity. Table 1Timeline of key clinical events and cardiac parameters, showing NT-proBNP (left), LVOT gradient, and EF (right) over time during mavacamten treatment Timeline of key clinical events and cardiac parameters, showing NT-proBNP (left), LVOT gradient, and EF (right) over time during mavacamten treatment Genetics Genetic testing performed during trial participation revealed a heterozygous likely pathogenic c.785A>T p.(Asn262Ile) variant in exon 7 of the RAF1 gene according to the ACMG criteria (PS1, PM1, PM2 and PP3), consistent with Noonan syndrome.8,9 Two additional variants of uncertain significance were identified (DSC2 c.1693A>G p.(Ile565Val); RYR2 c.8470C>T p.(Arg2824Trp)). Retrospective assessment revealed limited disease-specific red flags, except for the obstructive phenotype and remarkably early age at diagnosis.10 The patient had low to normal stature (165 cm), obesity (BMI 48), and joint hyperlaxity; however, there were no learning disabilities, no bleeding diathesis, no distinct facial dysmorphism, no congenital heart defects, and no family history of NS. The predominantly cardiac presentation, with limited extracardiac features, is consistent with the domain-specific phenotypic profile reported for Conserved Region 2 (CR2) variants in RAF1-related NS.11 Outcome The patient remained on mavacamten therapy for over 5 years and is currently treated with 10 mg daily. She remains clinically stable with NYHA class II symptoms and no recurrence of angina or presyncope. Treatment has been well-tolerated without adverse effects. Discussion While the majority of HCM cases are caused by pathogenic variants in sarcomeric genes, approximately 10% represent non-sarcomeric or syndromic phenocopies, including RASopathy-associated conditions such as NS.4 In particular, RAF1 mutations are strongly associated with severe obstructive phenotypes, reflecting hyperactivation of the Ras/MAPK pathway and downstream effects on myocardial growth and function.12,13 CMIs have emerged as an effective treatment for symptomatic oHCM by directly addressing sarcomeric hypercontractility. However, patients with syndromic or non-sarcomeric HCM phenocopies were systematically excluded from pivotal trials, resulting in limited evidence to guide treatment in these populations. Recently, a first clinical case reported favourable haemodynamic and symptomatic response to mavacamten in PTPN11-associated Noonan syndrome HCM. The present case extends these observations to a genetically distinct NS subtype, RAF1-related HCM.14 This calls for the evaluation of myosin inhibition across syndromic HCM subtypes. Despite distinct molecular drivers, the cardiac phenotype in our patient was indistinguishable from classical sarcomeric oHCM on echocardiography and CMR. This supports the concept that downstream functional abnormalities, most notably myocardial hypercontractility, may represent a convergent expression across genetically diverse forms of HCM (Figure 3). This hypothesis is also supported by recent preclinical data from an in vitro model of RASopathy-associated HCM, with a BRAF p.Thr599Arg activating mutation. The BRAF cardiomyocytes were characterized by hypertrophy, hypercontractility, impaired relaxation, and an energetic vulnerability under stress conditions. In this model, mavacamten normalized excessive ATP consumption, indicating that increased contractile energy demand, rather than impaired mitochondrial capacity, is a central pathological feature of RASopathy-associated HCM.15 Consistent with these findings, reduced energetic efficiency has also been observed in 3D cardiac tissues carrying the RAF1 p.Ser257Leu mutation.16 Proposed mechanism of myosin inhibition in Noonan syndrome–associated hypertrophic cardiomyopathy. Despite distinct upstream Ras/MAPK pathway activation, downstream myocardial hypercontractility represents a convergent pathophysiological mechanism. Myosin inhibition reduces excessive ATP consumption, improves relaxation, and alleviates dynamic obstruction, consistent with preclinical findings in RASopathy-associated cardiomyocytes. These findings provide a compelling mechanistic rationale for the sustained clinical response in our patient and suggest that sarcomere-level hypercontractility may be a shared downstream endpoint across sarcomeric and selected non-sarcomeric HCM genotypes, although potential effects of RYR2 and DSC2 variants on phenotype and mavacamten outcomes cannot be excluded. The 2023 ESC Guidelines for the management of cardiomyopathies emphasize the importance of phenotype-driven aetiological diagnosis of HCM, followed by a work-up to identify the underlying aetiology, including genetic testing. While the guidelines do not provide specific treatment recommendations for RASopathy-associated HCM, reflecting the absence of evidence from randomized trials in this population, they also acknowledge substantial knowledge gaps in the treatment of cardiomyopathy phenocopies and support individualized decision-making in expert centres.7 In this context, the therapeutic rationale in the present case was guided by the functional myocardial phenotype, specifically sarcomere-level hypercontractility, rather than genetic classification alone. Accurate genetic diagnosis is essential for risk stratification and clinical management. If genetic testing had been performed earlier, she would have been excluded from the EXPLORER-HCM trial and would not have received mavacamten. This points towards a general challenge in the treatment of syndromic cardiomyopathies, where rigid genotype-based exclusions limit access to potentially beneficial therapies. While this single case does not provide a basis for broader treatment recommendations, it underscores the need for dedicated preclinical and clinical investigation of myosin inhibition in RASopathy-associated and other HCM phenocopies. Taken together, this clinical report on the sustained benefit of myosin inhibition in NS–associated oHCM justifies systematic investigation in syndromic and non-sarcomeric HCM.